Landmark TAPUR™ Study Adds Two New Precision Drug Arms
ASCO, the American Society of Clinical Oncology, has expanded the Targeted Agent and Profiling Utilization Registry (TAPUR™) study.
The TAPUR study (NCT02693535), a phase 2...
AACR 2026: Conjugates Take Center Stage in Precision, Partnership, and Purpose-Driven Cancer Research
Antibody-drug conjugate (ADC) innovation continues at a remarkable pace, as evidenced by the 2026 Annual Meeting of the American Association for Cancer Research (AACR), held...
Ifinatamab Deruxtecan Receives FDA Priority Review for Previously Treated Extensive-Stage Small Cell Lung Cancer
Ifinatamab Deruxtecan (previously known as DS-7300a), a B7-H3-directed antibody-drug conjugate being developed by Daiichi Sankyo and Merck & Co. (known as MSD outside of the United States and Canada), could offer a First-in-Class option for patients diagnosed with extensive-stage small cell lung cancer (ES-SCLC) following platinum-based chemotherapy.
AbbVie Showcases Promising Phase 2 Data for Mirvetuximab Soravtansine in Platinum-Sensitive Ovarian Cancer at...
AbbVie Showcases Promising Phase 2 Data for Mirvetuximab Soravtansine in Platinum-Sensitive Ovarian Cancer at SGO 2026
First-in-Patient Phase I Combination Study of IDE849 and IDE161 in DLL3 Upregulated Solid Tumor...
The first patient (FIP) has been dosed in a Phase 1 clinical trial combining IDE849 (also known as SHR-4849), a potential first-in-class delta-like ligand 3 (DLL3)-targeting Topoisomerase I (Topo-I-) payload antibody drug conjugate (ADC), with IDE161, a potential first-in-class poly(ADP-ribose) glycohydrolase (PARG) inhibitor. Both drugs are being developed by IDEAYA Biosciences. The Phase 1 combination study will be evaluated in DLL3 upregulated solid tumor indications, including small cell lung cancer (SCLC), neuroendocrine tumors (NETs), neuroendocrine carcinomas (NECs), and melanoma.
AbbVie and RemeGen to Jointly Develop a Novel Bispecific Antibody for Advanced Solid Tumors
AbbVie and RemeGen to Jointly Develop a Novel Bispecific Antibody for Advanced Solid Tumors
Real-World Study Shows Inotuzumab Ozogamicin Achieves Meaningful Remission in R/R B-Cell ALL While Highlighting...
Inotuzumab ozogamicin (Besponsa®; Pfizer), a humanized anti-CD22 antibody-drug conjugate that has shown significant activity in adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) as demonstrated in the phase 3 INO-VATE trial *(NCT01564784), [1], has demonstrated encouraging remission rates as salvage therapy for patients with R/R B-ALL, with overall survival of 51.7% (SD 8.1%) and event-free survival of 32.4% (SD 8.0%).
Phase 3 Study Supports Sacituzumab Govitecan + Pembrolizumab as a Potential New Standard of...
Phase 3 Study Supports Sacituzumab Govitecan + Pembrolizumab as a Potential New Standard of Care in First-line PD-L1+ mTNBC
Rakuten Medical and LOTTE Biologics Sign Manufacturing Agreement
During the 44th J.P. Morgan Healthcare Conference, held January 12-15, 2026, in San Francisco (USA), Rakuten Medical and LOTTE Biologics signed a manufacturing agreement to strengthen Rakuten Medical's production capabilities for its innovative oncology therapy, Alluminox® platform-based photoimmunotherapy, which has been shown to induce rapid and selective cell killing.
Sichuan Kelun-Biotech Signs Collaborative Agreement with Crescent Biopharma; Receives IND and BTD from Chinese...
The Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) of China has approved an Investigational New Drug (IND) application for SKB105 (also known as CR-003 and PR-023), integrin beta-6 (ITGB6)-targeted antibody-drug conjugate (ADC) being developed by Sichuan Kelun-Biotech Biopharmaceutical, for the treatment of advanced solid tumors.
